To the full analysis
Buyback calculator for Alibaba Health Information Technology
Alibaba Health Information Technology stock: key metrics
0241.HKAlibaba Health Information Technology had an operating margin of 5.4% and a return on invested capital (ROIC) of 20% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | 22.7% | −26.4% | −22.6% |
| 2008 | 21.3% | −42.7% | −34.8% |
| 2009 | 4.8% | −48.3% | −53.9% |
| 2010 | 13.2% | −11.8% | −17.9% |
| 2011 | 10.1% | −8.4% | −7.1% |
| 2012 | 11.4% | −7.0% | −1.6% |
| 2013 | −2,533.9% | −269.8% | −260.2% |
| 2014 | 49.3% | −154.9% | −142.6% |
| 2015 | 53.7% | −440.9% | −273.1% |
| 2016 | 67.1% | −372.4% | −338.6% |
| 2017 | 39.4% | −41.6% | −43.7% |
| 2018 | 26.6% | −5.6% | −4.4% |
| 2019 | 26.1% | −1.9% | −1.6% |
| 2020 | 23.2% | −0.7% | −0.1% |
| 2021 | 23.3% | 0.4% | 2.2% |
| 2022 | 20.0% | −5.3% | −1.3% |
| 2023 | 21.3% | −0.1% | 2.0% |
| 2024 | 21.8% | 2.7% | 3.3% |
| 2025 | 24.3% | 5.2% | 4.7% |
| 2026 | 24.0% | 5.4% | 5.7% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | −20.3% | −14.7% | −6.8% |
| 2008 | −13.4% | −16.7% | −10.2% |
| 2009 | −31.4% | −26.3% | −24.5% |
| 2010 | −12.3% | −10.9% | −9.1% |
| 2011 | −6.5% | −11.5% | −4.7% |
| 2012 | −1.9% | −11.2% | −1.4% |
| 2013 | −11.4% | −16.8% | −9.0% |
| 2014 | −9.3% | −21.5% | −8.0% |
| 2015 | −6.1% | −13.0% | −5.8% |
| 2016 | −15.7% | −13.6% | −14.2% |
| 2017 | −17.6% | −36.6% | −12.4% |
| 2018 | −4.1% | −11.7% | −3.4% |
| 2019 | −2.9% | −4.3% | −1.4% |
| 2020 | −0.1% | −1.4% | −0.1% |
| 2021 | 2.4% | 2.0% | 2.0% |
| 2022 | −1.9% | −27.4% | −1.4% |
| 2023 | 3.5% | −0.8% | 2.6% |
| 2024 | 6.1% | 14.4% | 4.5% |
| 2025 | 8.8% | 21.8% | 6.8% |
| 2026 | 10.9% | 20.0% | 8.4% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 17 Jan 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.